Food and Drug Law Institute: 1st Annual Conference on Nanotechnology Law, Regulation and Policy
Nanotechnology was incorporated into more than $50 billion in manufactured goods last year, according to Lux Research. By 2014, the market will grow to $2.6 trillion. By 2011, over $15 billion in nano-enabled drugs and therapeutics will be sold—up from more than $3 billion in 2006. And industry experts project that nanotechnology will be incorporated into $20 billion worth of consumer food products by 2010.
Yet, despite this rapid commercialization, no nano-specific regulation exists anywhere in the world. Most regulatory agencies remain in an information-gathering mode—lacking the legal and scientific tools, information and resources they need to adequately oversee exponential nanotechnology market growth.
Now, for the first time, you’ll get to meet all the top officials from these government departments in one place and learn of their plans for regulating food and drug nanotech products. You’ll hear what’s really happening in Europe and Asia, on Wall Street, in the corridors of major corporations, in the more advanced laboratories, at forward-thinking universities and in the halls of Congress.
WilmerHale partner, James Czaban, will be moderating a panel at this event, co-sponsored by the Woodrow Wilson International Center for Scholars Project on Emerging Nanotechnologies, in partnership with Arizona State University and Burdock Group.
Stay current on our Insights & News, including updates related to the coronavirus (COVID-19).
Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.